替奈普酶在取栓前治疗缺血性卒中的成本效益分析
本研究基于EXTEND-IA TNK随机试验,对替奈普酶与阿替普酶在取栓前治疗大血管闭塞性缺血性卒中的成本效益进行事后分析。短期分析显示替奈普酶组总成本较低且获益更高,长期Markov模型显示替奈普酶具有成本效益的概率为100%。结论认为替奈普酶在取栓前使用极可能具有成本效益,可为医疗系统节省费用。
要点
- 替奈普酶在取栓前治疗大血管闭塞性卒中短期和长期均具成本效益。
- 长期模型显示替奈普酶组额外终身成本更低且获益更高。
- 推荐替奈普酶替代阿替普酶可能为医疗系统节省成本。
核心结论
- 基于EXTEND-IA TNK试验的经济分析表明,替奈普酶在取栓前治疗急性缺血性卒中极可能具有成本效益。
研究设计与样本
- 研究为EXTEND-IA TNK随机对照试验的事后经济分析,纳入202例患者,比较替奈普酶与阿替普酶的成本效益。
关键数值与推荐
- 短期分析中替奈普酶具有成本效益的概率为97.4%,长期分析中为100%。
临床怎么用
- 对于大血管闭塞性缺血性卒中患者,取栓前使用替奈普酶替代阿替普酶可能节省医疗成本并改善预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Tenecteplase improved functional outcomes and reduced the requirement for endovascular thrombectomy in ischemic stroke patients with large vessel occlusion in the EXTEND-IA TNK randomized trial. We assessed the cost-effectiveness of tenecteplase versus alteplase in this trial. METHODS: Post hoc within-trial economic analysis included costs of index emergency department and inpatient stroke hospitalization, rehabilitation/subacute care, and rehospitalization due to stroke within 90 days. Sources for cost included key study site complemented by published literature and government websites. Quality-adjusted life-years were estimated using utility scores derived from the modified Rankin Scale score at 90 days. Long-term modeled cost-effectiveness analysis used a Markov model with 7 health states corresponding to 7 modified Rankin Scale scores. Probabilistic sensitivity analyses were performed. RESULTS: Within the 202 patients in the randomized controlled trial, total cost was nonsignificantly lower in the tenecteplase-treated patients (40 997 Australian dollars [AUD]) compared with alteplase-treated patients (46 188 AUD) for the first 90 days(P=0.125). Tenecteplase was the dominant treatment strategy in the short term, with similar cost (5412 AUD [95% CI, -13 348 to 2523]; P=0.181) and higher benefits (0.099 quality-adjusted life-years [95% CI, 0.001-0.1967]; P=0.048), with a 97.4% probability of being cost-effective. In the long-term, tenecteplase was associated with less additional lifetime cost (96 357 versus 106 304 AUD) and greater benefits (quality-adjusted life-years, 7.77 versus 6.48), and had a 100% probability of being cost-effective. Both deterministic sensitivity analysis and probabilistic sensitivity analyses yielded similar results. CONCLUSIONS: Both within-trial and long-term economic analyses showed that tenecteplase was highly likely to be cost-effective for patients with acute stroke before thrombectomy. Recommending the use of tenecteplase over alteplase could lead to a cost saving to the healthcare system both in the short and long term. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02388061.
引用
- Gao L, Moodie M, Mitchell PJ, et al. Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke. Stroke. 2020. PMID: 33023423. doi:10.1161/STROKEAHA.120.029666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。